This company has been marked as potentially delisted and may not be actively trading. NASDAQ:OPTN OptiNose (OPTN) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About OptiNose Stock (NASDAQ:OPTN) Get OptiNose alerts:Sign Up Key Stats Today's Range$9.60▼$9.6050-Day Range$9.38▼$9.7152-Week Range$9.18▼$9.75VolumeN/AAverage Volume71,189 shsMarket Capitalization$97.22 millionP/E RatioN/ADividend YieldN/APrice Target$9.00Consensus RatingHold Company Overview OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania. Read More Receive OPTN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for OptiNose and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. OPTN Stock News HeadlinesParatek Pharmaceuticals Completes Acquisition of Optinose, Creating an Expanded Portfolio of Specialty TherapiesMay 21, 2025 | finance.yahoo.comOptinose Stockholders Approve Merger with ParatekMay 16, 2025 | tipranks.comIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially the reasons why we’re bombing the country.May 8 at 1:00 AM | Banyan Hill Publishing (Ad)OPTINOSE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of OptiNose, Inc. - OPTNApril 29, 2025 | businesswire.comOptinose Reports 2024 Financial Results, Highlights Prescription Growth and First Operational IncomeMarch 28, 2025 | msn.comOptinose reports Q4 EPS (3c) vs ($1.33) last yearMarch 27, 2025 | markets.businessinsider.comOptinose Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational HighlightsMarch 26, 2025 | markets.businessinsider.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GB, RDFN, PRA, OPTN on Behalf of ShareholdersMarch 25, 2025 | morningstar.comMSee More Headlines OPTN Stock Analysis - Frequently Asked Questions How were OptiNose's earnings last quarter? OptiNose, Inc. (NASDAQ:OPTN) posted its quarterly earnings data on Tuesday, May, 13th. The company reported ($1.01) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.74) by $0.27. The company earned $18.51 million during the quarter, compared to the consensus estimate of $17.70 million. When did OptiNose's stock split? OptiNose shares reverse split before market open on Tuesday, December 31st 2024.The 1-15 reverse split was announced on Thursday, December 26th 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, December 30th 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. When did OptiNose IPO? OptiNose (OPTN) raised $120 million in an initial public offering (IPO) on Friday, October 13th 2017. The company issued 7,500,000 shares at $15.00-$17.00 per share. Jefferies, Piper Jaffray, BMO Capital Markets and RBC Capital Markets acted as the underwriters for the IPO. What other stocks do shareholders of OptiNose own? Based on aggregate information from My MarketBeat watchlists, some other companies that OptiNose investors own include NVIDIA (NVDA), GE Aerospace (GE), Meta Platforms (META), Broadcom (AVGO), Arista Networks (ANET) and Adobe (ADBE). Company Calendar Last Earnings5/13/2025Today5/08/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:OPTN CIK1494650 Webwww.optinose.com Phone(267) 364-3500FaxN/AEmployees190Year Founded2000Price Target and Rating Average Price Target for OptiNose$9.00 High Price Target$9.00 Low Price Target$9.00 Potential Upside/Downside-6.3%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)($3.00) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$35.48 million Net Margins-41.16% Pretax Margin-41.16% Return on EquityN/A Return on Assets-27.42% Debt Debt-to-Equity RatioN/A Current Ratio0.79 Quick Ratio0.72 Sales & Book Value Annual Sales$81.86 million Price / Sales1.19 Cash FlowN/A Price / Cash FlowN/A Book Value($11.56) per share Price / Book-0.83Miscellaneous Outstanding Shares10,127,000Free Float9,829,000Market Cap$97.22 million OptionableNot Optionable Beta-0.88 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:OPTN) was last updated on 5/8/2026 by MarketBeat.com Staff. From Our PartnersOne executive order. The biggest wealth transfer of your lifetime.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredI’m sounding the alarmMeta is cutting 10% of its workforce. Microsoft offered voluntary retirement to 7% of U.S. employees. Oracle, ...Porter & Company | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredIs the SpaceX IPO “Rigged?”The SpaceX IPO filing is official, with 21 banks - including JPMorgan, Goldman Sachs, and Morgan Stanley - pre...The Oxford Club | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredMassive Data Leak Exposes 512,000-Line Code That Could Change Society Forever"You won't believe what I discovered at 4 World Trade Center" When our financial media correspondent travel...Chaikin Analytics | SponsoredIf You'd Followed Nancy Pelosi's Stock Picks, You'd Be 43% Richer Than Everyone ElseNancy Pelosi's portfolio gained 71 percent in 2024 while the S&P 500 returned just 28 percent. In 2023, she ea...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OptiNose, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share OptiNose With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.